Axonics Valuation
Is AXNX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AXNX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AXNX * (MX$1227) is trading below our estimate of fair value (MX$2914.62)
Significantly Below Fair Value: AXNX * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AXNX *?
Key metric: As AXNX * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is AXNX *'s PS Ratio? | |
|---|---|
| PS Ratio | 8.8x |
| Sales | US$408.81m |
| Market Cap | US$3.59b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8x |
| Enterprise Value/EBITDA | 442.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AXNX *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.3x | ||
688617 APT Medical | 16.7x | 29.3% | CN¥32.7b |
NARI Inari Medical | 5.2x | 15.0% | US$3.0b |
INSP Inspire Medical Systems | 6.8x | 16.1% | US$5.2b |
IRTC iRhythm Technologies | 4.5x | 15.0% | US$2.5b |
AXNX * Axonics | 8.8x | 16.5% | Mex$3.6b |
Price-To-Sales vs Peers: AXNX * is good value based on its Price-To-Sales Ratio (8.8x) compared to the peer average (10.3x).
Price to Sales Ratio vs Industry
How does AXNX *'s PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 139 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 139 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: AXNX * is expensive based on its Price-To-Sales Ratio (8.8x) compared to the Global Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is AXNX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AXNX *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Médica Sur. de
Mex$3.1b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$28.84
7D
-0.6%
1Y
-31.0%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a